Aspen Pharmacare Holdings (LDZA) Stock Price & Analysis
LDZA Stock Chart & Stats
- Day’s Range
- EUR 8.35 - EUR 8.35
- 52-Week Range
- EUR 4.54 - EUR 8.80
- Previous Close
- EUR 8.45
- Volume
- 0
- Average Volume (3M)
- 22
- Market Cap
- EUR 3.65B
- Enterprise Value
- EUR 4.22B
- Total Cash (Recent Filing)
- EUR 12.34B
- Total Debt (Recent Filing)
- EUR 36.46B
- Price to Earnings (P/E)
- 26.5
- Beta
- 0.35
- Next Earnings
- Mar 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.59%
Aspen Pharmacare Holdings News
LDZA FAQ
What was Aspen Pharmacare Holdings’s price range in the past 12 months?
What is Aspen Pharmacare Holdings’s market cap?
When is Aspen Pharmacare Holdings’s upcoming earnings report date?
How were Aspen Pharmacare Holdings’s earnings last quarter?
Is Aspen Pharmacare Holdings overvalued?
Does Aspen Pharmacare Holdings pay dividends?
What is Aspen Pharmacare Holdings’s EPS estimate?
How many shares outstanding does Aspen Pharmacare Holdings have?
What happened to Aspen Pharmacare Holdings’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aspen Pharmacare Holdings?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aspen Pharmacare Holdings
Operating worldwide, Aspen Pharmacare Holdings Limited, together with its subsidiaries, focuses on the development, production, and global distribution of specialized and branded pharmaceutical products. The company's business activities are structured into two main divisions: Commercial Pharmaceuticals and Manufacturing. Under its Anaesthetics portfolio, Aspen offers diverse products such as general anesthetics, muscle relaxants, and topical agents. Its Thrombosis brand is dedicated to a variety of injectable anticoagulants, with an emphasis on low molecular weight heparins, Xa inhibitors, and heparin derivatives. Additionally, Aspen provides a range of branded consumer, prescription, and over-the-counter medications through regional brands. These include Circadin (for sleep management), Foxair (for respiratory conditions), Maltofer (an iron supplement), Mybulen (a painkiller), and Zyloric (which controls uric acid production). Beyond its proprietary offerings, the company also manufactures and supplies active pharmaceutical ingredients (APIs) and finished dosage form products to external clients. Founded in 1850, Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Stephen Bradley Saad
- Employees
- 7,625
- Website
- www.aspenpharma.com
- Address
- Aspen Place, Durban, NL, 4321, ZA
Aspen Pharmacare Holdings (LDZA) Earnings & Revenues
LDZA Company Deck
LDZA Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic. Aspen reported substantial EBITDA, normalized earnings, margin, cash flow, and balance-sheet improvements despite flat group revenue, the loss of a major manufacturing contract, geopolitical impacts, restructuring charges, and a Canadian GLP-1 API issue. Management raised sterile manufacturing guidance and provided expectations for more than 50% normalized headline earnings growth in financial year 2027.
View all DE:LDZA earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 4 | 7 |
| Technical Analysis | 2 | 4 | 3 |
| Moving Averages | 8 | 0 | 4 |
